Immunotherapy against several tumors, such as lung cancer, including NSCLC

Patent metadata

Field	Value
Publication number	US-10071148-B2
Application number	US-201615357838-A
Country	US
Kind code	B2
Filing date	Nov 21, 2016
Priority date	Aug 5, 2013
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has non-small cell lung cancer, comprising administering to the patient a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of TLSSIKVEV (SEQ ID NO: 5),
wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with a human class I or II MHC molecule on the surface of the antigen presenting cell for a period of time sufficient to activate the T cells.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the peptide is in a complex with the class I MEW molecule.

7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

9. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

10. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

11. The method of claim 1 , wherein the contacting is in vitro.

12. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

13. The method of claim 12 , wherein the composition comprises an adjuvant.

14. The method of claim 13 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes.

15. The method of claim 1 , wherein the immune response comprises a cytotoxic T cell response.

16. The method of claim 1 , wherein the class I MEW molecule is HLA-A*0201.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Walter Steffen
• Fritsche Jens
• Song Colette
• Singh Harpreet

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K14/7051

  T-cell receptor (TcR)-CD3 complex · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• C12N9/6491

  Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23) · CPC title